Pulmonary hypertension combination therapy may lead to greater disease burden

October 22, 2012

Patients with pulmonary arterial hypertension (PAH) receiving combination therapy with intravenous (IV) PGI2 may suffer from greater disease burden compared with those receiving monotherapy or combination therapy, excluding IV PGI2.

Researchers from Massachusetts General Hospital and Novartis Pharma AG in Switzerland performed statistical tests on 446 patients with PAH, of which (a) 337 were receiving monotherapy; (b) 88 were receiving non-IV PGI2 combination therapy; and (c) 21 were receiving IV PGI2 .

Results showed that pulmonary vascular resistance, mean number of PAH-related hospitalizations, and dyspnea scores were highest in those treated with IV PGI2.

This study was presented during CHEST 2012, the annual meeting of the , held October 20 – 25, in Atlanta, Georgia.

Explore further: Women with pulmonary arterial hypertension have greater response to treatment than men

Related Stories

Recommended for you

Molecular Zika study finds possible target for tests, drugs

April 19, 2016

The molecular structure of the Zika virus as seen on x-ray crystallography revealed electrostatic differences in a key protein compared with other flaviviruses that might explain how it infects human cells, according to a ...

Zika virus may now be tied to another brain disease

April 10, 2016

The Zika virus may be associated with an autoimmune disorder that attacks the brain's myelin similar to multiple sclerosis, according to a small study that is being released today and will be presented at the American Academy ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.